Abstract An experimentally determined structure for human CYP2J2-a member of the cytochrome P450 family with significant and diverse roles across a number of tissues-does not yet exist. Our understanding of how CYP2J2 accommodates its cognate substrates and how it might be inhibited by other ligands thus relies on our ability to computationally predict such interactions using modelling techniques. In this study we present a computational investigation of the binding of arachidonic acid (AA) to CYP2J2 using homology modelling, induced fit docking (IFD) and molecular dynamics (MD) simulations. Our study reveals a catalytically competent binding mode for AA that is distinct from a recently published study that followed a different computational pipeline. Our proposed binding mode for AA is supported by crystal structures of complexes of related enzymes to inhibitors, and evolutionary conservation of a residue whose role appears essential for placing AA in the right site for catalysis.
Introduction
Cytochrome P450s (CYPs) form a large and diverse family of monooxygenase enzymes involved in the metabolism of both exogenous and endogenous substrates [1] . CYP2J2, the only member of the CYP2J subfamily in humans, is the primary source of arachidonic acid (AA)-derived epoxygenase products 5,6-, 8,9-, 11,12-and 14,15-epoxyeicosatrienoic acids (EETs) in human cardiac tissue [2] . In addition to the heart, the CYP2J2 mRNA is present in the liver, kidney and skeletal muscle, and, to a lesser extent, in the small intestine, pancreas, lung and brain [3] . Moreover, CYP2J2 expression can be induced in endothelial cells [4] and monocytes [5] by bacterial lipopolysaccharide. CYP2J2 is also expressed in a wide variety of tumors and tumor cell lines, where it appears to promote cell survival [6] . CYP2J2 and the EETs it produces have been shown to regulate the inflammatory response, vascular tone, cellular proliferation, angiogenesis, and metabolism [3] . In addition to AA, CYP2J2 can also metabolize the structurally related linoleic, docosahexaenoic and eicosapentaenoic acids to epoxy-products with biological activity [7, 8] .
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In addition to the metabolism of fatty acids, similar to many CYPs, CYP2J2 can accept a wide range of xenobiotic substrates for detoxification [9] [10] [11] . Using screens of marketed therapeutic agents, albendazole, amiodarone, cyclosporine A, danazol, mesoridazine, nabumetone, tamoxifen, thioridazine, telmisartan and flunarizine were all shown to be potential xenobiotic substrates for CYP2J2. Moreover, terfenadine [12, 13] and ebastine [13] have been used as the parent compounds to generate structure-based CYP2J2 inhibitors with K(I) values as low as 160 nM [12, 13] .
The roles of CYP2J2 in the physiology and pathophysiology of cardiovascular and tumor biology along with drug metabolism, have led to a quest for greater understanding of its structure. There is currently no crystal structure of CYP2J2. In the absence of an experimentally determined crystal structure, homology models represent an invaluable tool to progress our understanding of a protein's structure-function relationship [14] . Indeed, homology models of proteins that elude crystallization efforts (or have simply not yet been characterized) have contributed significantly to our understanding of their substrate specificity [15] and mode of action [16] , and facilitated structure-based ligand/inhibitor design to target these proteins [17, 18] .
Homology models of CYP2J2 have been built in previous studies (Supplementary Table S1 ) using a variety of related structures as templates. Lafite et al. [19] used structures of CYPs 2A6, 2B4, 2C5, 2C8 and 2D6 with resolutions ranging from 2.05 Å to 3.00 Å. The templates were chosen to provide the greatest diversity in the family, as well as in the occupancy of the active site (from no ligand to large ligands present). Li et al. [20] used a structure of CYP2C9 bound to warfarin as a template (resolution: 2.55 Å); however, the template used carried significant mutations in the F-G region and a thorough investigation of changes to substrate binding was not completed prior to crystallization [21] , raising doubts about its ability to represent the wild type protein. Lee et al. [9] created a model based on structures for CYPs 2B4, 2C8, and 2A6 at an average resolution of 2.1 Å, and their analyses focused on accessibility of a variety of ligands to the active site. Cong et al. [22] created a model based on the 2.8 Å resolution structure of CYP2R1 and concentrated on mutation-induced changes to AA binding based on known polymorphisms. Finally, more recently, Xia et al. [23] created a model based on CYP2A6, CYP2E1, CYP17A1, CYP2R1 and CYP2C8 as templates (resolutions ranging from 2.2 Å to 2.8 Å). The model was used to dock AA, and polymorphisms known to reduce the metabolism of AA were explained based on the binding mode observed in the docking study.
In the study presented here, we have investigated the binding of AA to CYP2J2 using a modelling approach that is also based on the principles of homology modelling and docking simulations. However, our strategy of selecting promising binding poses from induced fit docking and using them as starting points for 50 ns-long molecular dynamics (MD) simulations differs significantly from existing studies, and our results are also distinct. The only two modelling studies that have examined the binding of AA to CYP2J2 (Xia et al. [23] and Cong et al. [22] ) were partially carried out by the same authors and followed a very similar protocol in the building of their homology model. Cong et al. [22] carried out a 10 ns MD simulation in addition, but the main conclusions of the two studies are analogous. Both resulted in a protein-ligand complex where AA is tethered at the far end of the binding site channel by hydrogen bonds to Leu378 and Gly486. This model of binding relies on a hydrogen bond to the main chain of CYP2J2. We viewed this model with scepticism, as we believe that the need for specificity for AA would be better served by one or more residues anchoring it in place through side-chain interactions. To investigate further, we built our own homology model and carried out both docking and MD simulations of the binding of AA to CYP2J2.
We present here an alternative binding mode for AA to that suggested in the literature. This binding mode is supported by existing crystal structure complexes of proteins of the same family bound to inhibitors of diverse structures. Differences in our model and previously suggested models are reflected in the distinct list of residues that we put forward as being important for recognition, and, hence, being the most interesting for testing with mutagenesis experiments. In the absence of relevant experimental data, it is difficult to ascertain which model, if any, is correct. Hence, we believe that, until relevant experimental data become available, it is worth keeping in mind that binding modes distinct from those published so far are not only possible, but also plausible.
Methods
All computational modelling tasks, including protein preparation, docking and MD simulations were carried out using tools available in the Schrödinger molecular modelling software suite (http://www.schrodinger.com).
Generation of a 3D model of CYP2J2
The sequence of CYP2J2 was extracted from the Uniprot (http://www.uniprot.org) database entry with accession code P51589. This sequence was used to search the RCSB Protein Data Bank [24] (http://www.rcsb.org) using the 'Search by Sequences' facility. Selection of the template for the homology model was based on the following considerations: (1) the percentage sequence identity between CYP2J2 and putative templates, (2) the resolution of the crystal structures returned by the search, (3) the presence and type of ligand bound in the template, and (4) the completeness of the template protein chain (in terms of missing or mutated residues).
Only proteins with sequence identity to the query higher than 35 % were considered. Rabbit CYP2B4 (PDB ID: 1suo [25] ) was selected as the template for homology modelling based on a combination of relatively high sequence identity to CYP2J2 (39 %), completeness of sequence, and high resolution of the corresponding crystal structure (1.9 Å). This structure (PDB ID: 1suo) has not been used in the past for the construction of a homology model of CYP2J2, despite the fact that it has comparable sequence identity and higher resolution among most structures used so far to build models. The sequence alignment between rabbit CYP2B4 and human CYP2J2 ( Supplementary Fig. 1 ) justifies the use of the former as a template for modelling the latter. The ligand bound to CYP2 B4 in the crystal structure is 4-(4-chlorophenyl)imidazole-a compact ligand by comparison to AA. A model based on this structure would have a relatively small active site that would close in further during protein preparation for docking, as the protein side chains would tend to move closer to one another to maximize interactions. To allow the active site to remain open, we carried out protein preparation in the presence of a larger ligand, vitamin D3 (all three ligands mentioned in this study are depicted in Fig. S2 ). This ligand was positioned in the CYP2J2 active site by superimposing our model with the crystal structure of CYP2R1 (PDB ID: 3c6g [26] ), a human homologue crystallized with vitamin D3. Once the model CYP2J2 was optimized for docking, vitamin D3 was removed to leave a large, open active site ready for docking AA.
The template structure (PDB ID: 1suo) was prepared using the Protein Preparation Wizard tool [27] . Water molecules were deleted whilst the original ligand (CPZ) and heme molecules were retained. Prime [28] was used to generate the wild type homology model. The model was refined using the Protein Preparation Wizard and minimized using Prime Refinement. Analysis of the generated model with Verify3D [29] identified amino acids that were poorly modelled (Verify3D score was less than 0.2). These amino acids were then used as starting points for refinement using the Prime Brefinement with proximity^approach. This protocol involves two cycles of minimization: the first cycle involves amino acids proximal to the selected ones (starting at 1 Å), and the second involves a total minimization of the whole structure. The proximity cut-off was increased by 2 Å in each cycle, resulting in a total of 51 cycles for this protein. The minimized structures after each cycle were analysed with Verify3D and the best structure (in this case the result of the final cycle) was chosen.
The final model was assessed using the following structure assessment programs: Verify3D, ERRAT [30] , PROCHECK [31] , QMEAN [32] . Verify3D, ERRAT and PROCHECK were run on the server of the Molecular Biology Institute at the University of California, Los Angeles (http://services.mbi. ucla.edu). QMEAN score values were obtained from the QMEAN server at http://swissmodel.expasy.org/qmean.
Generation of a complex between CYP2J2 and AA
The 2D structure of AA was taken from the PubChem Compound [33] database and processed using Schrodinger's LigPrep [34] tool. Ionization states were assigned by Epik [35] at physiological pH (7.0). Parameters were assigned using the OPLS2005 force field [36] .
AA was docked into the active site of the CYP2J2 model using the Induced Fit Docking Protocol (IFD [37] ). Briefly, the first stage of this protocol scales down the van der Waals radii of both protein and ligand atoms by a factor of 0.5, and ligands are then docked into the fixed receptor using the Glide SP docking protocol. Next, Prime is used to predict the optimal orientation of the side chains of residues lining the binding site. Finally, the ligand is re-docked into the optimized binding site and poses are scored with Glide XP. A cubic box of 10 Å 3 was used for docking, centered on the original co-crystallized ligand in the template structure used for homology modelling. Twenty top-scoring poses were kept following IFD. The poses were viewed and five poses were selected manually as diverse starting points for MD simulations.
MD simulation of AA binding to CYP2J2
MD simulations were carried out using the Schrödinger interface of the Desmond program. Five MD runs were started from the five poses selected following IFD. The proteinligand complex was solvated in a cube of TIP3P waters, extended 15 Å away from any protein atom. The resulting system was then neutralized with the addition of sodium and chlorine ions at a concentration of 0.15 M. Periodic boundary conditions were applied to avoid finite-size effects. Atomic partial charges of ligands were maintained as obtained from the OPLS2005 force field. MD simulations were performed using Desmond v.2.4 and the OPLS2005 force field. The simulation protocol included starting relaxation steps and a final production phase of 50 ns at 300 K.
In particular, the starting relaxation steps comprised an initial minimization of the system over a maximum 2000 steps, with a convergence criterion of 50 kcal mol
, and the presence of harmonic restraints on the solute atoms (force constant = 50.0 kcal mol
); a second minimization without restraints; a third stage of 12 ps at 10 K with harmonic restrains on the solute heavy atoms (force constant = 50.0 kcal mol
), using NVT ensemble and Berendsen thermostat; a fourth 12 ps at 10 K, retaining the harmonic restraints, and using NPT ensemble and Berendsen thermostat and barostat; a fifth heating phase of 24 ps at 300 K, retaining the harmonic restraints, and using NPT ensemble and Berendsen thermostat and barostat; a final 24 ps at 300 K without harmonic restraints, using the NPT Berendsen thermostat and barostat. After the relaxation steps, a 50-ns MD simulation was carried out at 300 K using canonical bNPT Berendsen ensemble. During MD simulations, we used a time step of 2 fs while constraining the bond lengths of hydrogen atoms with the M-SHAKE algorithm [38] . The atomic coordinates were saved every 5 ps. Following simulations, the Schrödinger Simulations Interaction Diagram (SID) was employed for analysis. SID is a post-MD analysis tool available in the Schrödinger environment for the easy visualization and analysis of protein-ligand interactions derived from MD simulations. Figures 1, 3, 4 , and 5 were prepared using the software Chimera [39] . Where a superposition of two or more structures was necessary, Chimera's Match Maker was used in the global alignment mode. Figure 2 was prepared using output from the programs PROCHECK, QMEAN and ERRAT.
Preparation of figures
Figures 4a,b; 6; and 7 were prepared using the Schrödinger molecular modelling software.
All additional formatting of figures and addition of labels was done using the free image editor Gimp (http://www.gimp.org).
Results

Generation and validation of a homology model for human CYP2J2 from rabbit CYP2B4
A homology model of human CYP2J2 was built using the rabbit CYP2B4 (PDB ID: 1suo) as template. The model retained the overall fold of CYPs, with 12 major helices and four β sheets (Fig. 1) . The structural quality of the model was confirmed by a range of computational tools (Fig. 2) . The Ramachandran plot for the model (Fig. 2a) showed good stereochemistry for over 90 % of the residues (97.8 % of residues are in Bmost favoured^and Badditional allowed^regions, and only two of the 463 residues modelled were in disallowed regions). Verify3D reported 93.3 % of residues as having an average 3D−1D score ≥ 0.2. The calculated QMEAN score for this model was 0.77, and the associated Z-score was −0.03. The QMEAN score is an estimate of the Bdegree of nativeness^of the structural features in the model, and, as shown in Fig. 2b and c, this model displayed Bnativelike^features, when compared with a high quality reference dataset of structures. ERRAT, which uses statistics of non-bonded interactions in the model and compares them to those of high quality crystal structures, produced an overall quality factor of 77.1 %, meaning that 77.1 % of all residues had calculated error values below the 95 % rejection limit (Fig. 2d) . All these quality metrics are comparable with those reported in publications of existing models of CYP2J2. In addition, our model was compared to those listed in ModBase [40] as well as others built automatically by the Protein Model Portal [41] ( Table S2 ). The results show our model to be of comparable, or superior, quality (not unexpectedly, given the automated nature of these model builders). Furthermore, the models listed in Table S2 lack the heme moiety whilst our method preserves the co-factor in the final model. Cofactor exclusion or incorrect placement is a major drawback of using automated modelling servers, currently only circumvented by manual inclusion.
Finally, the active site volume of our model was calculated to be 234 Å 3 using the SiteMap [42] method. This value is similar to the volumes found by Xia et al. [23] (330 Å 3 ) and Cong et al. [22] (320 Å 3 ) but notably smaller than those reported by Lafite et al. [19] (945 Å 3 ) and Lee et al. [9] (1420 Å 3 ). There are several potential reasons for this discrepancy. The models may differ significantly in their conformation, but we cannot ascertain this, as we have no access to these models, and there are no coordinates deposited in a public repository. However, other more technical reasons may Fig. 1 of Cong et al. [22] The rest of the structure is shown in grey. c Superposition of the crystal structure of the template structure (rabbit CYP2B4; PDB ID: 1suo; grey) onto the homology model of human CYP2J2 (orange) also be responsible for the differences observed. Programs differ widely in their definition of a Bcavityâ nd the corresponding calculation of its volume. For example, the inclusion or exclusion of a solvent accessible channel leading to the heme whilst calculating the volume of the binding site could justify the differences between the reported values in the literature. In addition, the inclusion of heme itself could alter the results significantly due to the large volume occupied by this cofactor. Indeed, calculations of the active site volume using fpocket [43] or the cavities analysis from the PDBsum [44] server (http://www.ebi.ac.uk/thorntonsrv/databases/pdbsum/Generate.html) give much larger estimates for our model (1339 Å 3 and 1977 Å 3 , respectively), but it is clear from Fig. S3 that this is due to merging of cavities that are forming a channel towards the heme. Moreover, we show in Fig. S3 that a comparison of the active site volumes of different models may be less relevant, given that the movement of side chains during the MD run allows the sampling of conformations with considerable variation in the active site volume, at least as perceived by software.
IFD suggests that AA is tethered to the CYP2J2 active site by a hydrogen bond to Arg117
Following preparation of both the small molecule ligand and the protein, AA was docked into the active site of the CYP2J2 model using a flexible receptor protocol (IFD [37] , as described in the Materials and Methods). The 20 resulting poses of AA following the IFD protocol are depicted (superimposed) in Fig. 3 . In contrast to previously identified poses involving a hydrogen bond to the main chain atoms of Leu378, all our IFD poses showed the AA carboxylic group facing away from Leu378, and interacting with Arg117 instead. Hydrogen bonds to both side-and main-chain atoms of Arg117 were observed for the top ranking poses (Fig. 3b) but there was small variation in the positioning of the carboxylic acid among the lower-ranking of the 20 IFD poses, leading to slightly different interaction profiles with the protein (see examples of protein-ligand interaction diagrams in Fig. S4) . A hydrogen bond to the Arg117 side-chain was observed in 19 cases (the 20th only just failing the cut-off for the minimum acceptor angle), and, in 11 of the 20 poses the Arg117 backbone was also involved in a hydrogen bond with , the Met116 backbone was also hydrogenbonded to the AA carboxylate tail. In addition to the residues mentioned above, a channel to the active site was lined by a network of mostly hydrophobic residues, creating a favorable environment for the long non-polar AA chain. The following ten residues were in contact with the substrate in all 20 poses from IFD: Thr114, Phe121, Ile127, Asp307, Phe310, Ala311, Glu314, Thr315, Ile376 and Ile487, while there were several others that appeared in at least half the poses (e.g., Pro115, Ile120, Val218, Glu222, Trp251).
MD simulations of AA bound to CYP2J2 confirm the importance of Arg117 as a tether for the substrate
Five MD simulations were run (two for 30 ns and three for 50 ns) starting with five manually selected and diverse poses from the IFD runs. Here, we concentrate on analysis of one of the 50 ns runs (referred to here as run 2), which resulted in the most promising (from a catalysis point of view) and most stable (especially during the last nanoseconds of the simulation) position for the binding of AA to CYP2J2. We occasionally refer to the remaining MD runs in this section, where we believe it is instructive to do so.
The conformation of the protein did not change drastically during the simulation (Fig. 4a) . Although an increase in the average RMSD values for the protein C-alpha atoms was observed at around 35 ns of simulation, the RMSD values stayed within the 3 Å range, and so were within what might be expected from thermal fluctuations of a small globular protein.
Amino acids with the largest fluctuations during the simulation are highlighted in the root mean square fluctuation (RMSF) plot (Fig. 4b) , and map to highly flexible loops on the protein structure (Fig. 4c) , confirming that the increase in the average RMSD was not due to major restructuring of parts of the protein, but to expected fluctuations of flexible loops on the surface. By contrast, amino acids involved in the binding of the ligand appeared stable during the simulation and exhibited, as expected, the lowest fluctuations (Fig. 4b) . AA displayed a similar stability throughout the simulation, indicative of a narrow binding site that allows only restrained conformational movements (Fig. 4a) .
In the final frame of the 50 ns simulation, AA was positioned in a catalytically competent orientation within the small hydrophobic tunnel on top of the heme molecule (Fig. 5a) .
Comparison with the final frames from the remaining four simulations (Fig .S5a) highlight a number of ligand-binding poses that potentially represent AA en route to approaching the heme. Ligand-only RMSD values between the AA atoms of these four last frame snapshots, and the AA atoms of the last frame of run 2 vary from 3.4 Å to 9.3 Å. In run 2, the ω9 double bond positioned above the iron at a distance of approximately 3.5 Å in a plane parallel to the heme (Fig. 5b,c) . This distance fluctuated between 3 Å and 4.5 Å throughout most of the simulation (Fig. 6a) -a range consistent with distances previously described for a heme-catalyzed epoxidation reaction [45] . Literature data on the regioselectivity of this enzyme indicates epoxidation rates of 37 % for ω6 vs 18 % for ω9 [3] . Although this suggests a small preference for the ω6 bond, our simulation was not sensitive enough to reproduce this result. However, we did observe ω6 approaching the iron atom at around 30 ns, as is evident from the distance plot in Fig. 6b. ω9 showed the opposite profile, with its distance to iron increasing significantly in the same timeframe (Fig. 6a) . Finally, we also monitored the ω6 and ω9 distances from iron for two of the remaining four simulations (runs 3 and 7; the other two stay too far from the heme for this distance to be meaningful). During both these simulations, there are time slots when ω9 is at a reasonable distance (between 3 Å and 4 Å) from the iron atom but for most of the time the distances are longer than 4.5 Å and so unlikely to represent poses representative of a catalytic event (Fig. S5b) . The interaction of protein residues with AA during the 50 ns of the simulation are summarized in Fig. 7 . A number of hydrophobic residues that line the binding site stabilize the ligand in place (Phe310, Ile127, Ala311, Ile375, Ile376 and others). As the simulation progresses and the complex equilibrates, these interactions become stronger (at about 25 ns), and the ligand appears to stabilize further (Fig. 4a) . Similarly to what was seen in the induced-fit docking poses, Arg117, Met116, and Thr114 are involved in hydrogen bonds to the small molecule substrate, anchoring it in place. The most persistent hydrogen bonds Fig. 4 a-c Protein and ligand molecules remain relatively stable during 50 ns of MD simulation. a Time-dependent root mean square deviation (RMSD) of the protein C-alpha carbons (blue) and ligand (purple) atoms during the time of the MD simulation. The first frame is used as the reference for calculating RMSD values. The ligand RMSD is measured for the ligand heavy atoms after superimposing the protein-ligand complex on the protein backbone of the reference structure. Thus, the ligand RMSD in this case reflects how stable the ligand is with respect to the protein and its binding site. b Residue-specific root mean square fluctuations (RMSF) during the trajectory of the MD simulation. Highest-fluctuating residues are labelled on the plot. The original numbering of the residues can be obtained by adding 39 to the numbers on the x-axis. The labels on the peaks correspond to correct (canonical) labelling of CYP2J2. c Superposition of ten structures extracted every 1 ns from the period 35-45 ns of the MD simulation. Highly flexible residues (labelled and highlighted in orange) are, as expected, all in loops facing the solvent and away from the heme (sticks colored by heteroatom) and arachidonic acid (blue sticks) in the middle of the enzyme between AA and CYP2J2 were formed by Arg117 (53.8 % and 44.4 % of the simulation time the main-chain and side-chain nitrogens, respectively, were involved in a hydrogen bond to the ligand). Thr114 was involved in an equally persistent hydrogen bond through its side-chain (43.4 % of the time), whereas the hydrogen bond to the Met116 main chain nitrogen was observed less than half of that time (17.7 %) in this simulation. In the other two MD runs where the ligand approached the heme (runs 3 and 7), hydrogen bonds were again observed predominantly to Arg117, with one simulation (run 3) showing persistent hydrogen bonds to the main chain (76.2 %), whereas the other (run7) showed interactions with the side-chain nitrogens (50.7 and 19.9 %). Hydrogen bonds to the main-chain of Met116 were persistent only in run 3 (46.2 %) and almost absent in run 7 (4.6 %), whereas interactions with the Thr114 side chain were present in both runs for significant periods of time (run3: 25.3 %; run7: 29.9 %).
Discussion
In this study, we investigated binding of AA to CYP2J2 based on a homology model of the enzyme structure, IFD of AA to the enzyme and a 50 ns MD simulation that starts from realistic poses identified at the IFD stage. Our model structure of CYP2J2 is of high quality, as assessed by several tools (Verify3D, ERRAT, PROCHECK, and QMEAN). The core structure, and, importantly, the access channel, is similar to those reported in recent studies [19, 23, 46] , and lined in each case by the same hydrophobic residues (or a subset thereof). The convergence of models to the same core structure with a common access channel increases our confidence in our model. Where our model differs significantly from the pose suggested by Cong et al. [22] is in the suggested mode of recognition of the substrate AA. The difference appears to originate at least partially from the assignment of a protonated state to the AA carboxylate group. The pKa of AA is 4.82 (http://www.drugbank. ca/drugs/DB04557), making it likely to be mostly unprotonated at physiological pH. In our study, AA is unprotonated and hence able to take advantage of the strong hydrogen bonding capabilities of Arg117. Further evidence supporting the validity of our model is presented below.
A number of crystal structures of complexes of CYP2 with inhibitors support the binding mode for AA suggested by our study. In the structure of the inhibitor troglitazone bound to human CYP2C8 (PDB ID: 2vn0 [47] ), the position of the inhibitor position overlaps with the region occupied by the carboxylic acid of AA and interacts with Ser103, the residue corresponding to Arg117 in the sequence alignment of the two enzymes (Fig. S6a) . In the same structure, Thr364, which corresponds to Leu378 in CYP2J2, shows no interactions with the co-crystallized inhibitor. Other ligands in complex with related cytochrome P450s also appear to bind closer to residues equivalent to Arg117 than to residues equivalent to Leu378 (e.g., abiraterone bound to CYP17A1 (PDB ID: 3ruk [48] ), vitamin D3 bound to CYP2R1 (PDB ID: 3c6g [26] ), or bifonazole bound to CYP2B4 (PDB ID: 2bdm [49] )-see Supplementary Fig. 6b . There are, of course, crystal structures of CYP450s with inhibitors bound in different sites. Notably, the second bifonazole molecule bound to CYP2B4 is positioned closer to the Leu378 side of the pocket but further away from the heme moiety, and so likely represents a less catalytically relevant pose of the ligand. Similarly, warfarin bound to CYP2C9 (PDB ID: 1og5 [21] ) is positioned closer to Thr364 (the residue equivalent to Leu378) than to the Arg117 equivalent. However, warfarin is a bulky ligand with a very different shape to the flexible AA, and so differences between its binding and that of AA are not surprising.
Several docking studies further support our model. Lafite et al. [19] used their CYP2J2 model for docking the inhibitor terfenadone and its derivatives, and found that the keto group of terfenadone is held in place through hydrogen bonding interactions with the guanidine moiety of Arg117. Additionally, the hydrophobic part of terfenadone was accommodated in the narrow tunnel leading to the heme through a series of contacts to the same residues that we have identified as important in holding the hydrophobic part of AA. In the same study, three derivatives of terfenadone presented a similar interaction profile with CYP2J2. we observe ω9 at a distance ready for catalysis, at approximately 30 ns the ligand flips and ω6 becomes the bond approaching the heme in a catalytically competent distance Likewise, Li et al. [20] used a CYP2J2 model for docking studies of four ligands sharing the same scaffold: ebastine, terfenadine, terfenadone and a terfenadone derivative. Arg117 formed a hydrogen bond to ebastine, and, although it did not hydrogen bond to the other three ligands, it was listed as one of the residues contributing significant amounts of energy to the interaction. Similarly, in the Ren et al. [46] study (where the homology model of Li et al. [20] was used), inhibitors telmisartan and flunarizine bind in a pocket that includes Arg117, and the orientation of the carboxylic group of telmisartan after 2 ns of MD simulations suggests that a longer simulation might include poses that hydrogen bond to Arg117. Interestingly, telmisartan binds far from the heme group, yet it is a potent inhibitor of CYP2J2. In our model, blocking access of the substrate to Arg117 leads to the loss of an important hydrogen bond, which should make it easier for a ligand to compete for binding the enzyme.
Finally, a model where AA interacts with Arg117 is supported by evolutionary conservation of this residue. In the absence of a manually curated dataset of CYP2J2 enzymes from other organisms, we obtained an alignment of all members of the same protein family from Ensembl (protein family ID: PTHR24300_SF91). This is a broadly defined family with members that share the same Enzyme Commission number (E.C. 1.14.14.1) but not necessarily the same substrates. Examining the family sequence alignment, it appears at first that Arg117 is conserved in this family (61.8 % conservation within a group of 165 proteins) but to a lesser extent than Leu378, which shows 80 % conservation. However, on closer inspection, the majority of sequences with a residue other than arginine at this position either have much shorter sequences, and are thus unlikely to have the same function, or they originate from Uniprot/TrEMBL entries where functional annotation is either not present or assigned Fig. 7 a, b Protein-ligand contacts during the 50 ns simulation. a Hydrogen bonds (green) and hydrophobic interactions (purple) between protein and ligand atoms are monitored during the MD simulation and summarized in this plot. The height of the bars indicates the time that a given protein residue spends being involved in a type of interaction with the ligand. Met316, for example, is associated with a bar of approximate height 1, indicating that it is involved in a hydrogen bond across the full trajectory. Heights greater than 1 (such as the one seen for Arg117) are due to multiple contacts of the same type and of the same protein residue with a ligand molecule. b Protein-ligand contacts are monitored across the time of the simulation. Contacts by specific protein residues per frame of the trajectory are depicted in the bottom part with orange lines indicating a contact and a darker shade of orange indicating more than one contact per residue. The total number of contacts for all protein residues is monitored in the top panel (blue lines). Arg117, Thr114 and Met116 stand out as the residues with the highest number of contacts across the time of the simulation by sequence similarity only. Removing these sequences that are unlikely to be true orthologues, leaves a group of 64 sequences where arginine is prevalent (68 % conserved) but glutamine is also common at this position. Restricting the selection further to 15 sequences that both carry the label CYP2J2 in Ensembl and share at least 70 % sequence identity at the gene level (both for the target and the query sequences), reveals that Arg117 is conserved in all but one sequence (where it is replaced by glutamine-see Supplementary Fig. 7 ). Although it is hard to speculate about the significance of these findings, given the overall high sequence identities shared by these protein homologues, there appears to be some evolutionary pressure for conserving a good hydrogen bond donor at this position. Perhaps more interesting are the results of comparing CYP2J2 with its rat homologue CYP2J3, which shares 73.9 % sequence identity with the human enzyme (see alignment in Fig. S8 ). CYP2J3, like CYP2J2, metabolizes AA to EETs [50] . In both CYP2J2 and CYP2J3, Arg117 and the amino acids of the narrow hydrophobic tunnel to the heme, are conserved. In the rat enzyme, Met116 is substituted by a leucine-a very conservative substitution. In contrast, Leu378 and Gly486, the two residues suggested in the previous study [22] as interacting with AA are replaced in CYP2J3 by phenylalanine and serine respectively, despite the very high conservation of the two enzyme sequences. Although the model of Cong et al. [22] predicts an interaction of AA with the backbone of Leu378 and Gly486, which would lessen the impact of mutations in the sequence, conservation of Arg117 in a homologue known to bind AA is consistent with an important functional role for this residue.
Conclusions
Our homology model of CYP2J2, in combination with IFD calculations and 50 ns MD simulations have led us to suggest a new binding mode for AA, that differs significantly from the recent suggestions in the literature. The main difference in our model is the residue employed to anchor the hydrophilic tail of AA in place (primarily Arg117). The support for our results is two-pronged: first, the similarity of our proposed binding mode to that of the binding of inhibitors of CYP2J2 homologues in the literature; and second, the conservation of Arg117 and conservative substitution of Met116 in an enzyme in rat that performs the same reaction. Until relevant experimental data become available, we believe it is worth keeping this alternative mode of binding in mind, especially when designing mutagenesis experiments.
